Oral SERD Therapy in ER+/HER2- Metastatic Breast Cancer

Dr Vidula and Dr Lu describe how selective estrogen receptor degraders (SERDs) differ in their mechanism of action from other therapies for ER+/HER2– metastatic breast cancer and how newer SERDs differ from first-generation SERDs like fulvestrant.

Dr Lu reviews the efficacy of oral selective estrogen receptor degraders (SERDs) compared to other therapies for ER+/HER2– metastatic breast cancer.

Dr Vidula reviews the safety concerns associated with oral selective estrogen receptor degraders (SERDs) in comparison to other therapies for ER+/HER2– metastatic breast cancer.

A panel of experts discuss the potential benefits of using oral selective estrogen receptor degraders (SERDs) over other endocrine therapies for metastatic breast cancer in addition to the dosing schedule.

Drs Vidula and Lu discuss how the improved PFS seen with oral selective estrogen receptor degraders translates to clinical practice and the most recent NCCN guidelines.

Drs Vidula and Langer review the role of oral selective estrogen receptor degraders in the treatment of ER+/HER2- metastatic breast cancer and which patient populations would benefit most from oral SERDs.

Dr Lu discusses whether ESR1 mutation confirmation is required to consider therapy with oral selective estrogen receptor degraders.

Drs Langer and Vidula describe the coverage considerations for the diagnostic test required for the use of oral selective estrogen receptor degraders, best practices associated with its use, and the recommended duration of treatment.

Dr Lu and Dr Vidula review the clinical impact of oral selective estrogen receptor degraders (SERDs) on disease progression and response rates in patients with ER+/HER2- metastatic breast cancer and discuss if oral SERDs can be used in combination with other therapies in patients.

Drs Lu and Vidula discuss treatment failure with other agents that are used before oral selective estrogen receptor degraders (SERDs) and treatment resistance in patients with ER+/HER2- metastatic breast cancer.

Drs Vidula and Lu review the potential impact of cardiovascular health associated with oral selective estrogen receptor degraders (SERDs) and discuss how the risk of menopausal symptoms differ between oral SERDs and other endocrine therapies.

Drs Vidula and Lu discuss how to monitor patients for adverse effects or oral selective estrogen receptor degraders (SERDs) and how those adverse effects are managed.

Dr Langer explores how payers think about the authorization process for DEXA scans and other surveillance activities that would be required for selective estrogen receptor degraders (SERDs) and how oral SERDs affect quality of life.

Dr Langer reviews how physicians can ensure that patients get access to oral selective estrogen receptor degraders (SERDs), and the panel of experts provide their closing thoughts.

Sonya Negley, IOM, CSMA, reviews how patient advocates can help patients newly diagnosed with metastatic breast cancer.

Sonya Negley, IOM, CSMA, discusses ways to help patients with metastatic breast cancer feel empowered during their journey.

Sonya Negley, IOM, CSMA, describes the patient advocate’s role in helping patients with metastatic breast cancer discover and enroll in clinical trials.

An expert reviews best practices for assisting and guiding patients in their journey when navigating complex treatment decisions and options.

An expert describes the patient advocate’s role in shared decision-making with a patient for novel therapeutic options.

An expert reviews the role of the patient advocate in ensuring that health disparities in metastatic breast cancer are overcome.